1. Fungal endophthalmitis associated with compounded products.
- Author
-
Mikosz, Christina A, Smith, Rachel M, Kim, Moon, Tyson, Clara, Lee, Ellen H, Adams, Eleanor, Straif-Bourgeois, Susanne, Sowadsky, Rick, Arroyo, Shannon, Grant-Greene, Yoran, Duran, Julie, Vasquez, Yvonne, Robinson, Byron F, Harris, Julie R, Lockhart, Shawn R, Török, Thomas J, Mascola, Laurene, Park, Benjamin J, and Fungal Endophthalmitis Outbreak Response Team
- Abstract
Fungal endophthalmitis is a rare but serious infection. In March 2012, several cases of probable and laboratory-confirmed fungal endophthalmitis occurring after invasive ocular procedures were reported nationwide. We identified 47 cases in 9 states: 21 patients had been exposed to the intraocular dye Brilliant Blue G (BBG) during retinal surgery, and the other 26 had received an intravitreal injection containing triamcinolone acetonide. Both drugs were produced by Franck's Compounding Lab (Ocala, FL, USA). Fusarium incarnatum-equiseti species complex mold was identified in specimens from BBG-exposed case-patients and an unopened BBG vial. Bipolaris hawaiiensis mold was identified in specimens from triamcinolone-exposed case-patients. Exposure to either product was the only factor associated with case status. Of 40 case-patients for whom data were available, 39 (98%) lost vision. These concurrent outbreaks, associated with 1 compounding pharmacy, resulted in a product recall. Ensuring safety and integrity of compounded medications is critical for preventing further outbreaks associated with compounded products. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF